Innate Pharma announces worldwide exclusive license with Clinical Data Inc.
IPH 1201 enters in pre-clinical and pharmaceutical development
Encouraging data on IPH 1101 with final results from phase I clinical trial in solid tumours
New TLR assets from Schering-Plough Corporation and advanced R&D collaboration with IGR
Strategic partnership with Novo Nordisk to research and develop drugs targeting NK
Refocus of partnership with Novo Nordisk A/S
IPH 2301 enters into regulatory pre-clinical development
Results for Phase IIa study with IPH 1101 in mRCC
Encouraging data on IPH 1101 at the ASCO annual meeting
IPH 1101 in combination with rituximab enters the second part of the Phase I/II trial in fNHL
